

COMPANY ANNOUNCEMENT

CTA Laboratory Closes its operations in Parkville

28th April 2011, Melbourne Australia : Cancer Trials Australia (CTA) announced today that the Board of Directors had taken the decision to close down the operations of its clinical trial/translational laboratory.

CEO, Marcus Clark advised, " It's a very sad moment for the group as the Laboratory has been in existence since 2005 and assisted many Australian biotech companies with the development of their first assays for clinical trials. Unfortunately it has struggled financially due to trends by Pharma groups to centralise much target assay work. Engagement with such groups is pivotal to the sustainability of such an operation and we haven't been successful in gaining such business.

We are in the process of assigning contracts to other Laboratories and this has been assisted by the invaluable help of Melbourne Health Pathology who have been our landlord as well as collaborator on many projects. Melbourne Health is a founding member of CTA and our needs for laboratory services will often be provided via this strong relationship.

Our thanks to Dr John Barlow and his staff who have provided expertise and customer service over the last years."

About Cancer Trials Australia (CTA)

CTA is a Clinical Trial Network and Site Service Organisation providing research governance, advisory and laboratory assay services to investigators and sponsors of clinical trials in the field of oncology. Its member's organisations are:

Alfred Health
Austin Health
Ballarat Health
Bendigo Health
Border Medical Oncology
Cabrini Health
Ludwig Institute for Cancer Research
Melbourne Health
Peninsula Oncology Centre
Peter MacCallum Cancer Centre
St.Vincent's Hospital (Melbourne)
Southern Health
The Walter and Eliza Hall Institute
The Royal Women's Hospital
Tweed Hospital
Western Health

For further information on CTA please contact:
Mr. Marcus Clark, Chief Executive Officer CTA - 03 9342 7306.